Risk factor
High price volatility
Profitability factor
Very low or no dividends
About
Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices worldwide. The company offers ischemic stroke thrombectomy, intracranial stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access devices. Its products are used for the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis, as well as for the treatment of hemorrhagic stroke. The company was formerly known as Shanghai Care Medical Technology Corporation Limited. Shanghai HeartCare Medical Technology Corporation Limited was incorporated in 2016 and is headquartered in Shanghai, the People's Republic of China.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'expens
Target Price
The average target price of 6609.HK is 20 and suggests 64% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to de
Buy
Sell